Basic and clinical studies in immune function and metabolism
免疫功能和代谢的基础和临床研究
基本信息
- 批准号:8565575
- 负责人:
- 金额:$ 75.19万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:
- 资助国家:美国
- 起止时间:至
- 项目状态:未结题
- 来源:
- 关键词:AcidosisAcuteAddressAffectAgeAmino AcidsAmmoniaAnimalsAreaArginineArgininosuccinate lyase deficiencyBiological ModelsCD3 AntigensCatabolismCell Differentiation processCell MaintenanceCell physiologyCell surfaceCellsCellular biologyCitrullineCitrullinemiaClinicalClinical DataClinical ResearchCommunicable DiseasesCoupledCut proteinCytokine SignalingDefectDevelopmentDietDiseaseEnergy IntakeEnzymesEventFunctional disorderFutureGenesGeneticGoalsHepaticHepatitis A VaccinesHepatocyteHumanHyperammonemiaHypoglycemiaImmuneImmune System DiseasesImmune systemImmunityImmunizationIn VitroInborn Errors of MetabolismIndividualInfectionInfectious AgentInflammatoryInfluenzaIntoxicationLaboratoriesLeadLinkLiverLiver diseasesLongitudinal StudiesLymphopeniaMalnutritionManuscriptsMeasuresMediatingMedicalMemoryMesenteryMetabolicMetabolic DiseasesMetabolic PathwayMetabolismModelingMolecularMolecular BiologyMorbidity - disease rateMusNatureNutrition DisordersOrnithine carbamoyltransferase deficiencyPathologicPathway interactionsPatientsPerceptionPhenotypePlasmaPolyaminesPredispositionPreparationProcessProteinsProtocols documentationPublishingRare DiseasesRecruitment ActivityResearchRoleRunningSpleenT cell differentiationT-Cell ActivationT-Cell DevelopmentT-Cell ProliferationT-Cell ReceptorT-LymphocyteTimeTranslational ResearchUnited States National Institutes of HealthViremiaVirus DiseasesWorkadaptive immunityargininosuccinate lyaseargininosuccinate synthaseclinically significantcytokinegene replacement therapyimmune activationimmune functionin vivoinsightinterestlymph nodesmetabolomicsmouse modelnovelprogramsprospectiveprotein intakerespiratoryresponsestable isotopetreatment strategyurea cyclevaccine efficacy
项目摘要
Summary: Our translational research program studies intermediary metabolism and the immune system with a focus on inborn errors of metabolism. Intermediary metabolism is critical for the activation and differentiation of T-cells. Abnormalities in these pathways may lead to defects in effector and memory T-cell functions. Using a combination of mouse genetics, metabolomics, fluxomics, molecular and cell biology, and mouse models of inborn errors of metabolism, our goals are to understand how intermediary metabolism contributes to the normal function of cells in the immune system and their dysfunction in inborn errors of metabolism. This immune dysfunction may be primary or secondary. Genes involved in intermediary metabolism may be expressed in T-cells. In addition, intoxication phenotypes (e.g. acidosis or hyperammonemia) may also precipitate immune dysfunction. We are particularly interested in how these pathways affect responses to infectious diseases and immunization.
In addition, we also focus on disruptions of hepatic metabolism due to activation of the immune system systemically and locally. Hepatic metabolic decompensations in inborn errors of metabolism (e.g. hyperammonemia, acidosis, hypoglycemia) are most often precipitated by infection.
Specifically our aims are:
1) To understand how intermediary metabolism affects T cell development, differentiation and function. A special focus is placed in understanding how metabolic enzyme defects and intoxication phenotypes in inborn errors of metabolism affect T-cell effector and memory cell differentiation and function in response to immunization and infection. This work is being pursued in the laboratory with mouse models as well as affected patients in the NIH clinical center.
2) To understand how immune activation systemically or locally can precipitate hepatic metabolic dysfunction in inborn errors of metabolism. Our current work focuses on modeling respiratory viral infection-induced hepatopathy and resultant hyperammonemia in mouse models of urea cycle disorders. We are working on the mechanisms of cytokine and viremia induced urea cycle dysfunction.
Research:
Intermediary metabolism and T-cells: Over the past year we have spent our time characterizing the role of the amino acids citrulline and arginine in T-cell function. For T-cells, arginine is essential for T-cell proliferation and maintenance of the T-cell receptor. In T-cells deprived of arginine, the CD3 zeta chain and T-cell receptor are downregulated from the cell surface reducing proliferation. Using stable isotopes, the fate ultimate fate of arginine so far seems to be protein and polyamine synthesis. These pathways are currently being dissected out further. During arginine deficiency states, such as during an infection, cells may utilize citrulline by upregulating argininosuccinate synthetase (ASS1) and argininosuccinate lyase (ASL) to make arginine. ASS1 and ASL are also enzymes of the hepatic urea cycle. This implies that individuals with urea cycle disorders due to ASS1 (citrullinemia) or ASL (argininosuccinic aciduria) deficiencies may have a conditional immune defect under low arginine conditions. To answer these questions, we used a mouse model of citrullinemia. These animals are unable to convert citrulline to arginine and have hypercitrullinemia and hyperammonemia. Pathologic studies revealed that these mice had T and B lymphopenia, small spleens, and absent mesenteric lymph nodes. Since most of the animals die by 3 weeks of age, in conjunction with the Venditti laboratory, we developed a liver-targeted gene replacement therapy approach. This approach would also allow us to study cell autonomous ASS1 defects. To date, we have rescued several animals, which still retain the ASS1 defect in their T-cells. We are currently in the process of evaluating T-cell function using influenza A immunization and natural infection approaches. To address the effects of systemic intoxication with ammonia on immune function, we are working with another model of a urea cycle disorder, the spf-ash mouse (ornithine transcarbamylase deficiency (OTC)). These mice are hyperammonemic at baseline. Immunization studies against influenza thus far have demonstrated reduced vaccine efficacy against natural infection. We are continuing to characterize the nature of this defect, concentrating on aspects of ammonia intoxication of T-cells. To accomplish this, we are characterizing a new model of OTC deficiency, the spf-j, which will be published by our lab shortly. The advantage of this model over previous models is that the mouse is also hyperammonemic but on a clean B6 background unlike its predecessor. These basic studies have extended to the NIH Clinical Center. Our protocol titled the NIH UNI Study: Urea Cycle Disorders, Nutrition and Immunity is up and running and actively recruiting patients. In this protocol we evaluate the development of adaptive immunity to influenza and Hepatitis A vaccines.
Immune activation and hepatic intermediary metabolic dysfunction:
Our second main area of work involves exacerbation of hepatic metabolic diseases by activation of the immune system. One of the most serious consequences of Urea Cycle Disorder (UCD) is acute hyperammonemia (HA), which may be caused by dietary indiscretion (i.e. high protein intake), dietary deficiency resulting in enhanced catabolism, and acute infection. Acute HA is caused most often by infectious precipitants. There is also a perception that the acute HA that develops is clinically different from other precipitants: higher plasma ammonias of longer duration. Using clinical data from the Rare Disease Clinical Research Network sponsored prospective longitudinal study of the Urea Cycle Disorders Consortium, we were able to show that acute HA due to infection is a distinct clinical entity and displays markers of increased morbidity. This manuscript is in preparation.
Although enhanced catabolism is present during dietary deficiency as well as acute infection, we hypothesized that immune activation with inflammatory cytokine release may have more direct effects on hepatic urea cycle function. In support of this idea, we performed in vitro studies in primary human hepatocytes from controls and UCD patients, which demonstrated deleterious effects of inflammatory cytokines on ammonia metabolism. To examine this mechanism in vivo, we developed a model system of acute HA due to infection using two well-defined models, mouse adapted influenza A/PR/8 and the spf-ash mouse, a model of OTC deficiency. Via fluxomic and targeted metabolomic studies, we demonstrated that influenza infection results in unique perturbations in the disposal of ammonia and the availability of anaplerotic intermediates of the urea cycle. The clinical significance and translational importance of these findings are highlighted in the current management of acute HA in UCD. Regardless of the acute HA precipitant, the medical management strategy is the same: cut protein intake for 1-2 days, and provide high caloric intake. These measures are not always successful. Our findings provide novel insight into the metabolic pathophysiology behind acute infection, provides evidence for the use of alternative pathways of ammonia disposal in the spf-ash mouse and the possibility of applying anaplerotic intermediates or immune modifiers. This suggests that the ubiquitously applied treatment strategy of reversing catabolism during acute HA due to infection could be augmented. This work has resulted in a manuscript that is at present submitted for review. Future directions for this work include dissecting the molecular and metabolic events behind urea cycle inhibition. We will focus on cytokine signaling in hepatocytes and links to metabolism as well as viremia induced hepatopathy.
摘要:我们的转化研究项目研究中间代谢和免疫系统,重点是先天性代谢错误。中间代谢对t细胞的激活和分化至关重要。这些通路的异常可能导致效应t细胞和记忆t细胞功能的缺陷。结合小鼠遗传学、代谢组学、通量组学、分子和细胞生物学以及小鼠先天性代谢错误模型,我们的目标是了解中间代谢如何促进免疫系统中细胞的正常功能及其在先天性代谢错误中的功能障碍。这种免疫功能障碍可能是原发性的,也可能是继发性的。参与中间代谢的基因可能在t细胞中表达。此外,中毒表型(如酸中毒或高氨血症)也可能导致免疫功能障碍。我们对这些途径如何影响对传染病和免疫的反应特别感兴趣。此外,我们还关注由于全身和局部免疫系统激活而导致的肝脏代谢破坏。先天性代谢缺陷(如高氨血症、酸中毒、低血糖)引起的肝代谢失代偿最常由感染引起。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Peter McGuire其他文献
Peter McGuire的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Peter McGuire', 18)}}的其他基金
Metabolism, infection and immunity in inborn errors of metabolism
先天性代谢缺陷中的代谢、感染和免疫
- 批准号:
10025122 - 财政年份:
- 资助金额:
$ 75.19万 - 项目类别:
Basic and clinical studies in immune function and metabolism
免疫功能和代谢的基础和临床研究
- 批准号:
8750713 - 财政年份:
- 资助金额:
$ 75.19万 - 项目类别:
Metabolism, infection and immunity in inborn errors of metabolism
先天性代谢缺陷中的代谢、感染和免疫
- 批准号:
8948396 - 财政年份:
- 资助金额:
$ 75.19万 - 项目类别:
Metabolism, infection and immunity in inborn errors of mitochondrial metabolism
线粒体代谢先天性缺陷的代谢、感染和免疫
- 批准号:
10920205 - 财政年份:
- 资助金额:
$ 75.19万 - 项目类别:
Metabolism, infection and immunity in inborn errors of metabolism
先天性代谢缺陷中的代谢、感染和免疫
- 批准号:
9152751 - 财政年份:
- 资助金额:
$ 75.19万 - 项目类别:
Metabolism, infection and immunity in inborn errors of metabolism
先天性代谢缺陷中的代谢、感染和免疫
- 批准号:
9570584 - 财政年份:
- 资助金额:
$ 75.19万 - 项目类别:
Metabolism, infection and immunity in inborn errors of mitochondrial metabolism
线粒体代谢先天性缺陷的代谢、感染和免疫
- 批准号:
10267110 - 财政年份:
- 资助金额:
$ 75.19万 - 项目类别:
相似海外基金
Transcriptional assessment of haematopoietic differentiation to risk-stratify acute lymphoblastic leukaemia
造血分化的转录评估对急性淋巴细胞白血病的风险分层
- 批准号:
MR/Y009568/1 - 财政年份:2024
- 资助金额:
$ 75.19万 - 项目类别:
Fellowship
Combining two unique AI platforms for the discovery of novel genetic therapeutic targets & preclinical validation of synthetic biomolecules to treat Acute myeloid leukaemia (AML).
结合两个独特的人工智能平台来发现新的基因治疗靶点
- 批准号:
10090332 - 财政年份:2024
- 资助金额:
$ 75.19万 - 项目类别:
Collaborative R&D
Acute senescence: a novel host defence counteracting typhoidal Salmonella
急性衰老:对抗伤寒沙门氏菌的新型宿主防御
- 批准号:
MR/X02329X/1 - 财政年份:2024
- 资助金额:
$ 75.19万 - 项目类别:
Fellowship
Cellular Neuroinflammation in Acute Brain Injury
急性脑损伤中的细胞神经炎症
- 批准号:
MR/X021882/1 - 财政年份:2024
- 资助金额:
$ 75.19万 - 项目类别:
Research Grant
KAT2A PROTACs targetting the differentiation of blasts and leukemic stem cells for the treatment of Acute Myeloid Leukaemia
KAT2A PROTAC 靶向原始细胞和白血病干细胞的分化,用于治疗急性髓系白血病
- 批准号:
MR/X029557/1 - 财政年份:2024
- 资助金额:
$ 75.19万 - 项目类别:
Research Grant
Combining Mechanistic Modelling with Machine Learning for Diagnosis of Acute Respiratory Distress Syndrome
机械建模与机器学习相结合诊断急性呼吸窘迫综合征
- 批准号:
EP/Y003527/1 - 财政年份:2024
- 资助金额:
$ 75.19万 - 项目类别:
Research Grant
FITEAML: Functional Interrogation of Transposable Elements in Acute Myeloid Leukaemia
FITEAML:急性髓系白血病转座元件的功能研究
- 批准号:
EP/Y030338/1 - 财政年份:2024
- 资助金额:
$ 75.19万 - 项目类别:
Research Grant
STTR Phase I: Non-invasive focused ultrasound treatment to modulate the immune system for acute and chronic kidney rejection
STTR 第一期:非侵入性聚焦超声治疗调节免疫系统以治疗急性和慢性肾排斥
- 批准号:
2312694 - 财政年份:2024
- 资助金额:
$ 75.19万 - 项目类别:
Standard Grant
ロボット支援肝切除術は真に低侵襲なのか?acute phaseに着目して
机器人辅助肝切除术真的是微创吗?
- 批准号:
24K19395 - 财政年份:2024
- 资助金额:
$ 75.19万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Acute human gingivitis systems biology
人类急性牙龈炎系统生物学
- 批准号:
484000 - 财政年份:2023
- 资助金额:
$ 75.19万 - 项目类别:
Operating Grants